Lopez-Matas M, Rodriguez-Justo M, Morilla R, Catovsky D, Matutes E
Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, Institute of Cancer Research, London, UK.
Haematologica. 2000 Nov;85(11):1140-5.
Cells from the great majority of patients with chronic lymphocytic leukemia (CLL) express CD23. A recent histologic study has shown that CD23 is expressed more strongly in the proliferating centers of the lymph nodes, where the large prolymphocytoid cells are located. The aim of our study was to quantify the expression of CD23 and CD21 in small and prolymphocytoid cells from patients with CLL and B-cell lymphomas, and correlate this expression with clinical parameters.
Using quantitative flow cyto-metry we analyzed the antigen density of CD23 and CD21 in: 1) 101 cases of chronic lymphocytic leukemia, 84 typical, 14 with increased prolymphocytes (CLL/PL) and 3 atypical, 2) 15 cases of CD23 positive B-cell lymphoma with circulating lymphoma cells and 3) 8 normal subjects. The results were correlated with morphology and clinical staging.
Cells from CLL and CLL/PL have a significantly higher number of CD23 molecules than normal and lymphoma B-cells (p<0.001 and p<0.001, respectively). Differences were not significant for CD21. CLL and CLL/PL cases had similar values of CD23 and CD21 molecules, but analysis at a single level showed that prolymphocytes in typical CLL and CLL/PL expressed significantly higher CD23 (p=0.001, p=0.006) and CD21 (p=0.001, p=0.001) than small lymphocytes. There was no correlation between CD23 or CD21 antigen density and clinical stages although there was a trend for a brighter CD23 in stage C patients.
Since interaction between CD23 and CD21 is important for B-cell activation, proliferation and tumor formation, findings that both molecules are upregulated in prolymphocytes suggest that this is the proliferating cell component in CLL and underline the association between progression and increased prolymphocytes in typical CLL and CLL/PL.
绝大多数慢性淋巴细胞白血病（CLL）患者的细胞表达CD23。最近一项组织学研究表明，在大原淋巴细胞所在的淋巴结增殖中心，CD23表达更强。我们研究的目的是量化CLL患者及B细胞淋巴瘤患者小淋巴细胞和原淋巴细胞中CD23和CD21的表达，并将这种表达与临床参数相关联。
我们使用定量流式细胞术分析了以下样本中CD23和CD21的抗原密度：1）101例慢性淋巴细胞白血病，84例典型病例，14例原淋巴细胞增多型（CLL/PL）及3例非典型病例；2）15例伴有循环淋巴瘤细胞的CD23阳性B细胞淋巴瘤；3）8名正常受试者。结果与形态学及临床分期相关联。
CLL及CLL/PL患者的细胞中CD23分子数量显著高于正常及淋巴瘤B细胞（分别为p<0.001和p<0.001）。CD21方面差异不显著。CLL及CLL/PL病例的CD23和CD21分子值相似，但单水平分析显示，典型CLL及CLL/PL中的原淋巴细胞表达的CD23（p=0.0个1，p=0.006）和CD21（p=0.001，p=0.001）显著高于小淋巴细胞。CD23或CD21抗原密度与临床分期之间无相关性，尽管C期患者的CD23有更亮的趋势。
由于CD23与CD21之间的相互作用对B细胞激活、增殖及肿瘤形成很重要，两种分子在原淋巴细胞中均上调的结果表明，这是CLL中的增殖细胞成分，并强调了典型CLL及CLL/PL中病情进展与原淋巴细胞增多之间的关联。
